| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/14/2006 | US20060205646 Methods for increasing cell and tissue viability |
| 09/14/2006 | US20060205645 Administering a vascular endothelial growth factor (VEGF120, VEGF188 or VEGF165); intra-uterine or intra-amniotically to a fetus; intra-tracheal to a neonate |
| 09/14/2006 | US20060205644 Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R |
| 09/14/2006 | US20060205643 Treatment of ischemia/reperfusion injury of the intestine, inflammatory bowel disease, acute infective colitis or pseudomembranous colitis by parenteral administration of high density lipoprotein |
| 09/14/2006 | US20060205642 Oral methods of treatment using proANF peptides |
| 09/14/2006 | US20060205641 VANILREP4 polypeptides and VANILREP4 polynucleotides |
| 09/14/2006 | US20060205640 Cationic peptide that inhibits the growth of both grampositive and/or gramnegative bacteria; isolated from the hemocytes of the sea squirt; can be used to treat antibiotic resistant tuberculosis, pneumonia, and urinary pathologies |
| 09/14/2006 | US20060205639 composition for administering to eye, comprising tricaprin, ethyl lactate and surfactants sorbitan oleate, and cyclosporin; high bioavailability |
| 09/14/2006 | US20060205637 Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity |
| 09/14/2006 | US20060205636 Oxytocin as cardiomyogenesis inducer and uses thereof |
| 09/14/2006 | US20060205634 Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| 09/14/2006 | US20060205633 Therapeutic agent for diabetes |
| 09/14/2006 | US20060205074 Neural progenitor cells derived from whole bone marrow |
| 09/14/2006 | US20060205069 Compositions comprising a first agent which provides a primary activation signal to T cells and a second agent which stimulates an accessory molecule on the surface of T cells |
| 09/14/2006 | US20060205038 antagonist antibody that blocks binding of IL-17; degenerative cartilaginous disorders and other inflammatory diseases |
| 09/14/2006 | US20060205037 Modified transferrin fusion proteins |
| 09/14/2006 | US20060205036 Coagulation Factor VII polypeptides |
| 09/14/2006 | US20060205035 Expression vectors; transformed host cells; culturing the host cell to produce the encoded polypeptide; antiasthmatic agents |
| 09/14/2006 | US20060205031 Newly identified cholinephosphotransferases and ethanolaminephosphotransferases |
| 09/14/2006 | US20060205021 Mammalian IAP gene family, primers, probes and detection methods |
| 09/14/2006 | US20060205018 Polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides; use in therapy |
| 09/14/2006 | US20060205016 Protein a based binding domains with desirable activities |
| 09/14/2006 | US20060205008 Inhibiting association with survivin in presence of caspase; stimulates neoplastic cell death; treatment of liver disorders |
| 09/14/2006 | US20060205005 Artificial red blood cells |
| 09/14/2006 | US20060204994 Novel human protein kinases and protein kinase-like enzymes |
| 09/14/2006 | US20060204980 Colorectal cancer therapies |
| 09/14/2006 | US20060204966 selecting therapy for a human subject having a solid epithelial tumor that overexpresses ErbB2 comprising determining whether the tumor expresses p95ErbB2; reversible dual tyrosine kinase inhibitor of both ErbB2 and epidermal growth factor receptor |
| 09/14/2006 | US20060204962 Genetic polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy |
| 09/14/2006 | US20060204565 comprises a folate receptor ligand capable of binding to activated macrophages or a vitamin/vitamin-receptor binding analog and immunogen, a cytotoxin, or another compound capable of altering macrophage function |
| 09/14/2006 | US20060204549 Method of improving nutrient utilisation by a mammal and a composition for use therein |
| 09/14/2006 | US20060204540 provides release for a period of at least about two months; treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas |
| 09/14/2006 | US20060204529 Crosslinked elastin and process for producing the same |
| 09/14/2006 | US20060204525 Identifying compounds and methods using compounds which modulate interaction of lethal factor and anthrolysin O |
| 09/14/2006 | US20060204521 Vector carrying a polynucleotide which encodes a polypeptide having the ability to stimulate an immune response against the polypeptide of Seq ID No:24 |
| 09/14/2006 | US20060204515 Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi |
| 09/14/2006 | US20060204510 Bv8 nucleic acids and polypeptides with mitogenic activity |
| 09/14/2006 | US20060204501 Drug for cancer therapy |
| 09/14/2006 | US20060204499 Tumour necrosis factor binding ligands |
| 09/14/2006 | US20060204498 Novel antagonists of cxcr3-binding cxc chemokines |
| 09/14/2006 | US20060204492 Compositions and methods for producing enhanced antibodies |
| 09/14/2006 | US20060204490 Hemostatic compositions containing sterile thrombin |
| 09/14/2006 | US20060204489 Protein C derivatives |
| 09/14/2006 | US20060204488 using collagenase injections to lyse the collagenous adhesions in the shoulder and treat adhesive capsulitis or frozen shoulder |
| 09/14/2006 | US20060204487 Production of high mannose proteins in plant culture |
| 09/14/2006 | US20060204486 combination therapy of flibanserin with an antipsychotic drug |
| 09/14/2006 | US20060204483 determining whether a target cell expresses telomerase reverse transcriptase (TRT) by combining human T lymphocytes ex vivo with antigen-presenting cells containing a polypeptide that comprises at least 8 consecutive amino acids of telomerase reverse transcriptase |
| 09/14/2006 | US20060204477 Helper virus-free herpesvirus amplicon particles and uses thereof |
| 09/14/2006 | US20060204474 Treatment of epithelial layer lesions |
| 09/14/2006 | US20060204473 Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same |
| 09/14/2006 | US20060204471 Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging |
| 09/14/2006 | US20060204451 Chewing gum in the form of multi-layer tablets |
| 09/14/2006 | US20060204448 Powdery preparation for nasal administration |
| 09/14/2006 | US20060204446 Topical immunotherapy and compositions for use therein |
| 09/14/2006 | US20060204441 Cell scaffold matrices with incorporated therapeutic agents |
| 09/14/2006 | US20060204440 Radio-opaque polymeric biomaterials |
| 09/14/2006 | DE10244842B4 Für proteinspaltende Enzyme in Form von spezifischen Proteasen kodierende Nukleinsäuresequenzen, zugehörige Polypeptide und Verwendung von allen For protein-splitting enzymes in the form of specific proteases coding nucleic acid sequences associated polypeptides and use of all |
| 09/14/2006 | DE102005011779A1 Endoparasitizide Mittel Endoparasiticides means |
| 09/14/2006 | DE102005011111A1 Pharmaceutical composition comprising dendritic cells, useful for treating tumors, especially of the skin, where cells are loaded with animal toxins, formulated with a homeopathic component |
| 09/14/2006 | CA2605122A1 Thyrotropin-releasing hormone analogs and method of use |
| 09/14/2006 | CA2602007A1 Particle and preparation containing the particle |
| 09/14/2006 | CA2601279A1 Formulation for aviptadil |
| 09/14/2006 | CA2601271A1 Targeted plasminogen activator fusion proteins as thrombolytic agents |
| 09/14/2006 | CA2601133A1 Modified pyy (3-36) peptides and their effects on feeding behaviour |
| 09/14/2006 | CA2600946A1 Compositions and methods for inhibiting g protein signaling |
| 09/14/2006 | CA2600927A1 Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) to tissue using heme proteins as carriers |
| 09/14/2006 | CA2600749A1 Dimeric or multimeric microproteins |
| 09/14/2006 | CA2600638A1 Composition comprising emodepside and praziquantel or epsiprantel |
| 09/14/2006 | CA2600460A1 High pressure processing of metal ion lactoferrin |
| 09/14/2006 | CA2600370A1 Bioactive fus1 peptides and nanoparticle-polypeptide complexes |
| 09/14/2006 | CA2600113A1 Pharmaceutical liposomal compositions |
| 09/14/2006 | CA2600085A1 Microparticle and pharmaceutical preparation |
| 09/14/2006 | CA2599792A1 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| 09/14/2006 | CA2599723A1 Modified transferrin fusion proteins |
| 09/14/2006 | CA2599577A1 Nucleic acids and proteins and methods for making and using them |
| 09/14/2006 | CA2597485A1 Methods and compositions for modulating tweak and fn14 activity |
| 09/14/2006 | CA2597255A1 Natural ligand of g protein coupled receptor rcc356 and uses thereof |
| 09/14/2006 | CA2597244A1 Methods and compositions for the treatment of cancer |
| 09/14/2006 | CA2597213A1 Compositions and methods for treating or preventing flaviviridae infections |
| 09/13/2006 | EP1700921A2 Regulation of a human asparagine-hydroxylase |
| 09/13/2006 | EP1700920A1 Synthetic antibiotics |
| 09/13/2006 | EP1700918A2 Activatable recombinant neurotoxins |
| 09/13/2006 | EP1700868A2 A method for removing an antibody from blood or plasma |
| 09/13/2006 | EP1700867A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/13/2006 | EP1700863A1 Means and methods for producing polymers comprising peptide in a side chain |
| 09/13/2006 | EP1700606A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 09/13/2006 | EP1700605A2 Lyophilized methionine-containing protein preparations stabilized over long time |
| 09/13/2006 | EP1700603A2 Immunostimulatory nucleic acids |
| 09/13/2006 | EP1700120A2 Marker for neuromyelitis optica |
| 09/13/2006 | EP1700118A1 Retinal toxicity screening methods |
| 09/13/2006 | EP1699925A1 Il-23 and its receptor; related reagents and methods |
| 09/13/2006 | EP1699919A1 A respiratory syncytial virus with a genomic deficiency complemented in trans |
| 09/13/2006 | EP1699915A1 Tissue regeneration method |
| 09/13/2006 | EP1699823A2 Use of il-18 binding protein in inflammations |
| 09/13/2006 | EP1699822A2 Il-7 fusion proteins with antibody portions, their preparation and their use |
| 09/13/2006 | EP1699821A1 Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| 09/13/2006 | EP1699820A2 Neutralizing epitope-based growth enhancing vaccine |
| 09/13/2006 | EP1699819A2 Treatment of coronary or peripheral ischemia |
| 09/13/2006 | EP1699818A2 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use |
| 09/13/2006 | EP1699813A2 Isozyme-specific antagonists of protein kinase c |
| 09/13/2006 | EP1699809A2 Amniotic-derived peptide and uses thereof |